This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Let Go of These 4 Toxic Stocks Right Away
by Rimmi Singhi
Steer clear of toxic stocks like SRI, ILMN, TPIC and JD to safeguard your portfolio from losses.
Earnings Preview: Stoneridge (SRI) Q4 Earnings Expected to Decline
by Zacks Equity Research
Stoneridge (SRI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoneridge (SRI) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Stoneridge (SRI) delivered earnings and revenue surprises of 200.00% and 15.14%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Stoneridge (SRI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Stoneridge (SRI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Toxic Stocks to Discard From Your Portfolio Right Now
by Rimmi Singhi
If you own a toxic stock for long, you are likely to see a big loss in your wealth. Discarding them at the right time is the key to shield your portfolio from big losses.
Zacks.com featured highlights include: HealthEquity, Alarm.com, Stoneridge, Mercer and Bottomline Technologies
by Zacks Equity Research
Zacks.com featured highlights include: HealthEquity, Alarm.com, Stoneridge, Mercer and Bottomline Technologies
Analysts Estimate Stoneridge (SRI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Stoneridge (SRI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These 5 Toxic Stocks Could be Poisoning Your Portfolio
by Zacks Equity Research
Investors who can figure out the overpriced toxic stocks and shun them at the right time are the ones that are likely to benefit.
Zacks.com featured highlights include: Cushman Wakefield, Stoneridge, Bottomline Technologies, New Fortress Energy and Trinseo
by Zacks Equity Research
Zacks.com featured highlights include: Cushman Wakefield, Stoneridge, Bottomline Technologies, New Fortress Energy and Trinseo
5 Toxic Stocks to Get Rid Of or Play Short to Make Gains
by Zacks Equity Research
Figuring out toxic stocks and abandoning them at the right time is the key to shield your portfolio from big losses.
Earnings Preview: Stoneridge (SRI) Q1 Earnings Expected to Decline
by Zacks Equity Research
Stoneridge (SRI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for December 26th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for December 23rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Bleak Outlook for Electronics Miscellaneous Components Stocks
by Shalu Saraf
Electronics - Miscellaneous Components stocks are being impacted by trade war tensions. However, strong demand for electronic components will likely benefit the industry participants.
Twitter (TWTR) Q3 Earnings Miss, User Growth Aids Top Line
by Zacks Equity Research
Twitter's (TWTR) third-quarter 2019 results reflect product-related issues and higher-than-expected ad seasonality despite user growth.
MKS Instruments' (MKSI) Q3 Earnings Beat, Revenues Miss
by Zacks Equity Research
MKS Instruments' (MKSI) third-quarter 2019 results reflect weakness in the semiconductor market despite higher advanced market revenues.
Earnings Preview: Stoneridge (SRI) Q3 Earnings Expected to Decline
by Zacks Equity Research
Stoneridge (SRI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SRI or NJDCY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SRI vs. NJDCY: Which Stock Is the Better Value Option?
Earnings Preview: Stoneridge (SRI) Q3 Earnings Expected to Decline
by Zacks Equity Research
Stoneridge (SRI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SRI or OLED: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SRI vs. OLED: Which Stock Is the Better Value Option?
Is Stoneridge (SRI) A Great Pick for Value Investors?
by Zacks Equity Research
Is Stoneridge (SRI) a great pick from the value investor's perspective right now? Read on to know more.
Earnings Preview: Stoneridge (SRI) Q2 Earnings Expected to Decline
by Zacks Equity Research
Stoneridge (SRI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Stoneridge (SRI) Q1 Earnings Expected to Decline
by Zacks Equity Research
Stoneridge (SRI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoneridge (SRI) Reports Next Week: What Awaits?
by Zacks Equity Research
Stoneridge (SRI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoneridge (SRI) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stoneridge (SRI) delivered earnings and revenue surprises of 9.30% and 2.52%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?